Trial Summary:

Most patients with ovarian cancer present with advanced disease and, following debulking surgery, receive platinum-based chemotherapy. Patients who relapse less than 6 months after completing first-line chemotherapy are classified as 'platinum resistant' and have a median survival of 6-9 months. Patients whose disease progresses while they are on treatment are classified as having 'platinum refractory' disease.

This is a quality-of-life study measuring subjective improvement as well as objective response to estimate the benefit of palliative chemotherapy in women with platinum-resistant or refractory ovarian cancer. Objective response rates to chemotherapy in these patients are low. No large, randomised, controlled trials have yet reported the effect of systemic chemotherapy on symptom palliation and quality of life in patients with relapsed ovarian cancer.

Supported By:

Eligibility:

Women with platinum-resistant epithelial ovarian cancer

Registration ID:

ACTRN12607000603415

Participation:

International

Australian Lead Group:

ANZGOG

Status:

Closed

Activation Date:

8/05/2008

Chairs:

Michael Friedlander and Phyllis Butow (Australia)

Contact:

symptombenefit.study@sydney.edu.au